Regulus Therapeutics (RGLS) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

RGLS Regulus Therapeutics

Watchlist

1.6100
+0.0200+1.26%

Close Aug 16 16:00 ET

1.7000
+0.0900+5.59%

Post 19:46 ET

105.40MMarket Cap-1341P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Buy Rating Reaffirmed for Regulus Therapeutics Amidst Promising Clinical Data and Progress Towards Pivotal Trial
TipRanksAug 9 08:10 ET · Ratings
Regulus Therapeutics Q2 EPS $(0.17) Misses $(0.13) Estimate
BenzingaAug 8 17:34 ET
Express News | Regulus Therapeutics Inc: Ended Q2 2024 With Cash, Cash Equivalents, and Investments of $95.9 Mln; Cash Runway Into H1 2026
ReutersAug 8 16:43 ET
Regulus Therapeutics | 10-Q: Q2 2024 Earnings Report
SEC announcementAug 8 16:30 ET · Announcements
Express News | Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates
ReutersAug 8 16:05 ET
Express News | Regulus Therapeutics Q2 Operating Expenses USD 12.26 Million
ReutersAug 8 16:05 ET

Comments

Trytosaveabit

Aug 1 17:56

NFA! Because you asked!

So ive been asked by quite a few people that are newer traders! And because of being where we all have been. They are learning charts and where to enter and exit on momentum / day trades. But having a bit of trouble. Again as we all did and at times still do. Most know that because i cant know others risk tolerance. Or the type of trade they are doing? That i do not give buy / sell advice. But i was asked could i give some swing trade ideas, so they could have a chance to ...

Newbie93

Jun 28 10:05

$Regulus Therapeutics (RGLS.US)$ probably going to below 1$

Stock Region

Jun 25 18:14

Therapeutics Company Reports Positive Topline Data From Major Clinical Trial

Positive Topline Data from Regulus Therapeutics' Phase 1b MAD Clinical Trial of RGLS8429 for ADPKD.
Regulus Therapeutics Inc., a biopharmaceutical company listed on Nasdaq under the ticker symbol RGLS, has recently announced positive topline results from the third cohort of patients in its Phase 1b Multiple-Ascending Dose (MAD) clinical trial of RGLS8429. This investigational drug is being developed for the treatment of ...